Breast cancer is the most frequently diagnosed cancer in women and ranks second among
causes for cancer related death in women. Evidence in literature has shown that the past …

Progress has been made recently in developing antibody-drug conjugates (ADCs) that can
selectively deliver cancer drugs to tumor cells. In principle, the idea is simple: by attaching …

An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer
cells by combining the specificity of a monoclonal antibody (mAb) for a target antigen with …

Background The monoclonal antibody trastuzumab has survival benefit when given with
chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 …

Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy …

We performed a feasibility study to determine the optimal dosage and time of administration
of the monoclonal antibody zirconium‐89 (89Zr)‐trastuzumab to enable positron emission …

Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal …

Background Treatment with adjuvant trastuzumab for 1 year improves disease-free survival
and overall survival in patients with human epidermal growth factor receptor 2 (HER2) …

Purpose To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by
paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal …